Addex Therapeutics to present positive data on GABAB PAM for chronic cough treatment

From GlobeNewswire: 2025-06-05 01:00:00

Addex Therapeutics will present preclinical data from its GABAB PAM cough program at the 10th American Cough Conference in Dulles, VA on June 6-7, 2025. The company’s lead drug candidate is prepared to start IND enabling studies. GABAB receptors play a crucial role in treating chronic cough, with Addex targeting an allosteric site for potential advantages over current treatments. The company focuses on developing small molecule allosteric modulators for neurological disorders, including a drug candidate for substance use disorders. Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol “ADXN.”



Read more at GlobeNewswire: Addex to Present Positive GABAB PAM Chronic Cough Data at